dnay - DNAY STOCK NEWS

Codex DNA, Inc. (Nasdaq: DNAY) will showcase its automated BioXp™ system and RapidAMP™ cell-free DNA kit at the Antibody Engineering & Therapeutics Europe event from June 7-9, 2022. These tools aim to enhance antibody discovery processes by overcoming critical bottlenecks in gene synthesis and cloning. The BioXp system allows for rapid progression from digital antibody sequences to functional characterization in less than a day. The integrated technologies increase workflow efficiency, supporting researchers in synthesizing lead candidate domains swiftly and effectively.

Codex DNA, Inc. (Nasdaq: DNAY) reported a 142% revenue increase year-over-year for Q1 2022, totaling $5.6 million. Organic revenue growth was 82% after excluding Eton Bioscience contributions. The company saw record sales of BioXp™ systems and kit growth, while advancing its enzymatic DNA synthesis technology, SOLA. Operating expenses rose to $15.6 million due to headcount expansion, leading to a net loss of $13.2 million, compared to $7.4 million in Q1 2021. Cash reserves stand at $76.8 million as of March 31, 2022.

Codex DNA, Inc. (Nasdaq: DNAY) will release its Q1 2022 financial results on May 10, 2022, after market close. A conference call will follow at 1:30 p.m. PT to discuss results and corporate highlights. Investors can access the release and live webcast via their website. Codex DNA is recognized for its innovative synthetic biology solutions, including the BioXp™ system, which enables rapid and accurate DNA synthesis for various applications like precision medicine and genome editing.

Codex DNA, Inc. (Nasdaq: DNAY) announces its participation at the PEGS Boston Conference from May 2-6, 2022. The company will showcase its BioXp™ system and RapidAMP™ cell-free DNA kit, designed to streamline antibody-variable region synthesis and cloning. CEO Todd R. Nelson underscores the significance of the conference for biotherapeutics. The advanced technologies aim to address bottlenecks in therapeutic development, offering efficiency gains for researchers. The featured presentation will discuss optimizing workflows using BioXp™ on May 6.

Codex DNA (NASDAQ: DNAY) has successfully completed proof-of-concept demonstrations showcasing the efficacy of its technology in encoding digital data into DNA sequences. This breakthrough ensures accurate data retrieval and marks a step forward in developing next-generation DNA data storage tools. With DNA's superior storage capacity—potentially over 200 petabytes per gram—and longevity exceeding 1 million years, Codex DNA's automated workflows aim to revolutionize data storage. The company is leveraging proprietary algorithms and its BioXp™ system for efficient, high-fidelity data storage and retrieval.

Codex DNA (Nasdaq: DNAY) announced participation in the World Vaccine Congress on April 18-21, 2022, showcasing its BioXp™ system.

This automated workstation offers substantial improvements in quality, time, and cost for DNA and mRNA synthesis. It can synthesize high-quality DNA and mRNA within 24 hours, streamlining vaccine development processes.

Collaboratively with RNAimmune, Codex seeks to enhance mRNA delivery in vaccine discovery. Forward-looking statements about future products highlight growth potential.

Codex DNA (Nasdaq: DNAY) announced its participation at the SynBioBeta Built with Biology Global Conference from April 12-14, 2022, in Oakland, California. The company will showcase its innovative SOLA enzymatic DNA synthesis technology and BioXp™ products at booth #11. SOLA aims to enhance accuracy, scalability, and cost-effectiveness in synthetic biology workflows. Key presentations will be made by its executives, highlighting advancements in automated workflows for vaccine and therapeutic development.

Codex DNA, Inc. (DNAY) reported a successful fourth quarter and year-end 2021, achieving a 59% revenue increase to $3.1 million driven by product sales and collaborations. They signed a key licensing agreement with Pfizer and acquired Eton Bioscience, enhancing their growth strategy. Operating expenses rose to $13 million, contributing to a net loss of $12.5 million. The company anticipates 2022 total revenue between $19 million and $21 million with expected gross margins in the low to mid-forty percent range. Cash and equivalents stood at $82.8 million at year-end.

Codex DNA, Inc. (Nasdaq: DNAY) announced its first Investor R&D Webinar scheduled for March 29, 2022, at 8:00 a.m. PT. The webinar will highlight the company's R&D pipeline, particularly its proprietary Short Oligo Ligation Assembly (SOLA) enzymatic DNA synthesis technology. Attendees can pre-register via the provided link, and a live webcast will also be available on Codex DNA's Investor Relations website. As a leader in automated synthetic biology systems, Codex DNA aims to enhance the speed and accuracy of DNA and mRNA synthesis for various applications.